Ace­lyrin tops its $250M crossover with new $300M cash raise from blue-chip syn­di­cate

Shao-Lee Lin and her LA-based team at Ace­lyrin are back — and bring­ing its largest fi­nanc­ing haul yet.

The biotech re­port­ed a $300 mil­lion Se­ries C round Tues­day morn­ing, send­ing the com­pa­ny over the half-bil­lion dol­lar mark in ven­ture fi­nanc­ing since it was found­ed more than two years ago. The goal, ac­cord­ing to the biotech, is to push for­ward Phase III de­vel­op­ment of so-far sole can­di­date izok­ibep — in pso­ri­at­ic arthri­tis and ax­i­al spondy­loarthri­tis — through BLA sub­mis­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER